|
1
|
Ridolo E, Montagni M, Melli V, Bonzano L,
Incorvaia C and Canonica GW: A role for the intranasal formulation
of azelastine hydrochloride/fluticasone propionate in the treatment
of allergic rhinitis. Ther Deliv. 6:653–659. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brozek JL, Bousquet J, Baena-Cagnani CE,
Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T,
Schünemann HJ, et al: Allergic Rhinitis and its Impact on Asthma
(ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol.
126:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hadley JA, Derebery MJ and Marple BF:
Comorbidities and allergic rhinitis: Not just a runny nose. J Fam
Pract. 61(2 Suppl): S11–S15. 2012.PubMed/NCBI
|
|
4
|
Williams CM and Galli SJ: The diverse
potential effector and immunoregulatory roles of mast cells in
allergic disease. J Allergy Clin Immunol. 105:847–859. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Robbie-Ryan M and Brown M: The role of
mast cells in allergy and autoimmunity. Curr Opin Immunol.
14:728–733. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Woolhiser MR, Okayama Y, Gilfillan AM and
Metcalfe DD: IgG-dependent activation of human mast cells following
up-regulation of FcgammaRI by IFN-gamma. Eur J Immunol.
31:3298–3307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang JX, Kaieda S, Ameri S, Fishgal N,
Dwyer D, Dellinger A, Kepley CL, Gurish MF and Nigrovic PA:
IL-33/ST2 axis promotes mast cell survival via BCLXL. Proc Natl
Acad Sci USA. 111:10281–10286. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Juremalm M and Nilsson G: Chemokine
receptor expression by mast cells. Chem Immunol Allergy.
87:130–144. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okayama Y, Saito H and Ra C: Targeting
human mast cells expressing g-protein-coupled receptors in allergic
diseases. Allergol Int. 57:197–203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oskeritzian CA, Price MM, Hait NC,
Kapitonov D, Falanga YT, Morales JK, Ryan JJ, Milstien S and
Spiegel S: Essential roles of sphingosine-1-phosphate receptor 2 in
human mast cell activation, anaphylaxis, and pulmonary edema. J Exp
Med. 207:465–474. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bratcher PE, Weathington NM, Nick HJ,
Jackson PL, Snelgrove RJ and Gaggar A: MMP-9 cleaves SP-D and
abrogates its innate immune functions in vitro. PLoS One.
7:e418812012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vandenbroucke RE, Dejonckheere E and
Libert C: A therapeutic role for matrix metalloproteinase
inhibitors in lung diseases? Eur Respir J. 38:1200–1214. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gauchotte G, Marie B, Gallet P, Nguyen DT,
Grandhaye M, Jankowski R and Vignaud JM: Respiratory epithelial
adenomatoid hamartoma: A poorly recognized entity with mast cell
recruitment and frequently associated with nasal polyposis. Am J
Surg pathol. 37:1678–1685. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Purwar R, Kraus M, Werfel T and Wittmann
M: Modulation of keratinocyte-derived MMP-9 by IL-13: A possible
role for the pathogenesis of epidermal inflammation. J Invest
Dermatol. 128:59–66. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abel M and Vliagoftis H: Mast
cell-fibroblast interactions induce matrix metalloproteinase-9
release from fibroblasts: Role for IgE-mediated mast cell
activation. J Immunol. 180:3543–3550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brower GL, Chancey AL, Thanigaraj S,
Matsubara BB and Janicki JS: Cause and effect relationship between
myocardial mast cell number and matrix metalloproteinase activity.
Am J Physiol Heart Circ Physiol. 283:H518–H525. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tchougounova E, Lundequist A, Fajardo I,
Winberg JO, Abrink M and Pejler G: A key role for mast cell chymase
in the activation of pro-matrix metalloprotease-9 and pro-matrix
metalloprotease-2. J Biol Chem. 280:9291–9296. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abel M and Vliagoftis H: Mast
cell-fibroblast interactions induce matrix metalloproteinase-9
release from fibroblasts: Role for IgE-mediated mast cell
activation. J Immunol. 180:3543–3550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanbe N, Tanaka A, Kanbe M, Itakura A,
Kurosawa M and Matsuda H: Human mast cells produce matrix
metalloproteinase 9. Eur J Immunol. 29:2645–2649. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Silwal P, Shin K, Choi S, Kang SW, Park
JB, Lee HJ, Koo SJ, Chung KH, Namgung U, Lim K, et al: Adenine
suppresses IgE-mediated mast cell activation. Mol Immunol.
65:242–249. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dahiya S, Givvimani S, Bhatnagar S,
Qipshidze N, Tyagi SC and Kumar A: Osteopontin-stimulated
expression of matrix metalloproteinase-9 causes cardiomyopathy in
the mdx model of Duchenne muscular dystrophy. J Immunol.
187:2723–2731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hyc A, Osiecka-Iwan A, Niderla-Bielinska J
and Moskalewski S: Influence of LPS, TNF, TGF-ss1 and IL-4 on the
expression of MMPs, TIMPs, and selected cytokines in rat synovial
membranes incubated in vitro. Int J Mol Med. 27:127–137.
2011.PubMed/NCBI
|
|
24
|
McLeod JJ, Baker B and Ryan JJ: Mast cell
production and response to IL-4 and IL-13. Cytokine. 75:57–61.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bousquet J, Khaltaev N, Cruz AA, Denburg
J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica
GW, van Weel C, et al: Allergic Rhinitis and its Impact on Asthma
(ARIA) 2008 update (in collaboration with the World Health
Organization, GA(2)LEN and AllerGen). Allergy. 63 Suppl 86:S86–S88.
2008. View Article : Google Scholar
|
|
26
|
Bernstein DI, Schwartz G and Bernstein JA:
Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin
North Am. 36:261–278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim HY, Nam SY, Hwang SY, Kim HM and Jeong
HJ: Atractylone, an active constituent of KMP6, attenuates allergic
inflammation on allergic rhinitis in vitro and in vivo models. Mol
Immunol. 78:121–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin H, Zheng C, Li J, Yang C and Hu L:
Lentiviral shRNA against KCa3.1 inhibits allergic response in
allergic rhinitis and suppresses mast cell activity via PI3K/AKT
signaling pathway. Sci Rep. 5:131272015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang F, He W, Fanghui P, Wang L and Fan Q:
NF-kappaBP65 promotes invasion and metastasis of oesophageal
squamous cell cancer by regulating matrix metalloproteinase-9 and
epithelial-to-mesenchymal transition. Cell Biol Int. 37:780–788.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu Q and Stamenkovic I: Cell
surface-localized matrix metalloproteinase-9 proteolytically
activates TGF-beta and promotes tumor invasion and angiogenesis.
Genes Dev. 14:163–176. 2000.PubMed/NCBI
|
|
31
|
Gupta A, Zhou CQ and Chellaiah MA:
Osteopontin and MMP9: Associations with VEGF expression/secretion
and angiogenesis in PC3 prostate cancer cells. Cancers (Basel).
5:617–638. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu Y, Blokhuis BR, Garssen J and Redegeld
FA: Non-IgE mediated mast cell activation. Eur J Pharmacol.
778:33–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee CC, Huang HY and Chiang BL:
Lentiviral-mediated interleukin-4 and interleukin-13 RNA
interference decrease airway inflammation and hyperresponsiveness.
Hum Gene Ther. 22:577–586. 2011. View Article : Google Scholar : PubMed/NCBI
|
